New York – The Artificial Intelligence (AI) in drug discovery market is projected to surge to $6.89 billion by 2029 from $1.86 billion in 2024, demonstrating a robust compound annual growth rate (CAGR) of 29.9%. This significant expansion underscores the transformative impact of AI on pharmaceutical research and development, a key theme for the upcoming Decoding Bio AI x Bio Summit. The fourth annual summit, hosted by Decoding Bio, is scheduled for July 23, 2026, at the New York Stock Exchange.
The summit aims to unite operators, investors, scientists, and founders actively shaping the intersection of AI and biology. According to Mo Islam, co-founder and CEO of Arkaea Media Group, which recently acquired Decoding Bio, this event is a crucial platform for addressing the evolving landscape of medicine. Islam stated that the acquisition of Decoding Bio is part of Arkaea Media's strategy to "own the media channels around all critical technology."
AI is fundamentally reshaping the drug development process, from initial discovery to clinical trial design and protein engineering. Industry data indicates that AI can significantly reduce the traditionally lengthy and costly drug development timelines, with repurposed drugs potentially reaching the market in 3-12 years with an average investment of $300 million, compared to 10-15 years and $100 million to $2 billion for novel drugs. The summit will feature confirmed sessions with top pharmaceutical executives and AI-first drug discovery companies discussing successful partnerships.
Discussions will also delve into critical capital questions facing the field, with insights from late-stage and crossover fund partners. Healthcare and biotech leaders from frontier AI labs are expected to explore what a therapeutics company will look like in the next decade. The event emphasizes the growing demand for efficient drug development, driven by the need to shorten R&D cycles and leverage large biological datasets.
Attendance at the exclusive New York event is by application, with early bird passes available for a limited period. The summit provides a unique opportunity for stakeholders to engage in nuanced conversations and foster collaborations that will define the future of medicine.
